Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Hao Chen

Matched on ORCID iD 0000-0002-5151-3346; OpenAlex author ID A5100645927. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers

Papers 10

  1. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  2. Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. Co-author DOI 10.1016/j.canlet.2024.217134↗
  3. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Last author DOI 10.1038/s41467-023-40314-w↗
  4. Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Co-author DOI 10.1186/s13045-023-01506-5↗
  5. LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2411868/v1↗
  6. The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Co-author DOI 10.1186/s13045-022-01338-9↗
  7. Original study: The rescue staging for pancreatic ductal adenocarcinoma with inadequate examined lymph nodes. Co-author DOI 10.1016/j.pan.2021.02.010↗
  8. Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03985-1↗
  9. Preoperative Plasma D-Dimer Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Radical Resection Co-author DOI 10.21203/rs.3.rs-308863/v1↗
  10. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic … Co-author DOI 10.1186/s12943-017-0738-0↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chenghong Peng · 8 shared papers, 2017–2024 · strength 1.06
  2. Baiyong Shen · 7 shared papers, 2017–2024 · strength 0.96
  3. Lingxi Jiang · 6 shared papers, 2021–2024 · strength 0.89
  4. Xiaxing Deng · 4 shared papers, 2021–2024 · strength 0.59
  5. Zengyu Feng · 3 shared papers, 2022–2023 · strength 0.45
  6. Kexian Li · 3 shared papers, 2022–2023 · strength 0.45
  7. Kai Qin · 3 shared papers, 2022–2023 · strength 0.45
  8. Lijie Han · 3 shared papers, 2023–2024 · strength 0.44
  9. Yizhi Cao · 3 shared papers, 2023–2024 · strength 0.44
  10. Chenlei Wen · 3 shared papers, 2017–2024 · strength 0.40
  11. Weishen Wang · 3 shared papers, 2017–2024 · strength 0.35
  12. Dongfeng Cheng · 3 shared papers, 2017–2024 · strength 0.35
  13. Xiaxing Deng · 3 shared papers, 2017–2024 · strength 0.35
  14. Siyi Zou · 2 shared papers, 2021–2024 · strength 0.32
  15. Yongsheng Jiang · 2 shared papers, 2023–2024 · strength 0.30
  16. Jiaxin Luo · 2 shared papers, 2023–2024 · strength 0.30
  17. Youwei Zhu · 2 shared papers, 2023–2024 · strength 0.29
  18. Meilin Xue · 2 shared papers, 2023–2024 · strength 0.29
  19. Jiancheng Wang · 2 shared papers, 2021–2023 · strength 0.28
  20. Jiewei Lin · 2 shared papers, 2021–2023 · strength 0.28
  21. Baiyong Shen · 2 shared papers, 2021–2022 · strength 0.28
  22. Qian Zhan · 1 shared paper, 2024 · strength 0.18
  23. Jiejie Qin · 1 shared paper, 2024 · strength 0.15
  24. Xiaomei Tang · 1 shared paper, 2024 · strength 0.15
  25. Shuyu Zhai · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.